FDA Approves Promega’s OncoMate® MSI Dx System as a Companion Diagnostic for KEYTRUDA® in MSI-High Solid Tumors

Promega Receives FDA Approval for OncoMate® MSI Dx System as Companion Diagnostic for Merck’s KEYTRUDA®

Promega has received approval from the U.S. Food and Drug Administration (FDA) for its OncoMate® MSI Dx Analysis System as a companion diagnostic for Merck’s immunotherapy KEYTRUDA® (pembrolizumab). The newly approved diagnostic is designed to identify patients with microsatellite instability-high (MSI-H) solid tumors who may be eligible for treatment with the anti-PD-1 therapy.

The approval represents another regulatory milestone for Promega’s molecular diagnostic technology and expands its role in supporting treatment decisions in precision oncology. The OncoMate® MSI Dx Analysis System uses a polymerase chain reaction (PCR)-based approach to evaluate microsatellite instability status in solid tumor tissue. Determining a tumor’s MSI status can provide clinically relevant information that helps healthcare professionals identify patients who may benefit from specific cancer therapies.

The FDA approval was supported through a collaboration between Promega and Merck, which markets KEYTRUDA® in the United States and Canada and operates as MSD in other markets. The companies are working together to advance personalized medicine by connecting diagnostic testing with targeted therapeutic decisions and supporting the use of biomarker information in cancer care.

The latest approval builds on previous regulatory clearances and approvals for the OncoMate® MSI Dx Analysis System in the United States and other international markets. The test has already been used in clinical settings to support the identification of patients who may require additional evaluation for Lynch syndrome and to help identify certain patients with microsatellite stable (MSS) endometrial carcinoma who may benefit from treatment with KEYTRUDA® in combination with LENVIMA® (lenvatinib).

The expanded FDA-approved indication for MSI-H solid tumors adds another application for Promega’s diagnostic platform and reinforces the importance of molecular testing in selecting appropriate treatment options for patients with cancer.

FDA Approval Expands the Role of OncoMate® in Precision Oncology

The OncoMate® MSI Dx Analysis System is a PCR-based molecular diagnostic designed to assess microsatellite instability in solid tumor tissue. Microsatellite instability is a molecular feature associated with changes in repetitive DNA sequences known as microsatellites. These changes can occur when the DNA mismatch repair system, which normally corrects errors that arise during DNA replication, does not function properly.

Tumors with high levels of microsatellite instability are classified as MSI-H. A related biomarker category is mismatch repair deficiency (dMMR), which describes tumors in which the DNA mismatch repair system is impaired. Both MSI-H and dMMR status can have important implications for cancer diagnosis, treatment selection and clinical management.

Identifying MSI-H status can help clinicians determine whether a patient may be eligible for certain immunotherapy treatments. In particular, the FDA-approved companion diagnostic application connects the OncoMate® MSI Dx Analysis System with KEYTRUDA®, Merck’s anti-PD-1 immunotherapy.

Companion diagnostics are tests used to provide information that is essential for the safe and effective use of a corresponding therapeutic product. They help healthcare professionals identify patients whose tumors have specific biomarkers associated with potential treatment benefit.

In this case, the OncoMate® system is designed to identify patients with MSI-H solid tumors who may be considered for KEYTRUDA® treatment under the applicable FDA-approved indication. The test therefore supports a biomarker-driven approach to cancer care, in which molecular characteristics of a tumor can help inform therapeutic decisions.

The approval also expands the potential clinical utility of Promega’s MSI testing technology, which has previously received regulatory recognition for several other applications in oncology.

PCR-Based Testing Supports MSI Status Assessment

The OncoMate® MSI Dx Analysis System uses polymerase chain reaction technology to evaluate microsatellite instability in tumor tissue. PCR is a widely used molecular biology technique that enables targeted DNA regions to be amplified so they can be analyzed.

Microsatellites are short, repetitive DNA sequences distributed throughout the human genome. Under normal circumstances, DNA mismatch repair proteins help maintain the stability of these sequences by correcting errors that occur during DNA replication.

When the mismatch repair system is deficient, errors can accumulate in microsatellite regions. This can result in changes in the length of repetitive DNA sequences and lead to an MSI-H classification.

MSI testing is an important component of precision oncology because the biomarker can help guide treatment decisions in selected cancer types and clinical settings. Identifying patients with MSI-H tumors may help healthcare professionals determine whether a patient could be eligible for immunotherapy based on the relevant treatment indication.

The availability of an FDA-approved companion diagnostic provides clinicians with a regulated testing option to assess MSI status in solid tumor tissue for the specified KEYTRUDA® application.

By combining molecular diagnostic testing with therapeutic development, Promega and Merck aim to support more informed treatment decisions and help connect eligible patients with therapies that may be appropriate for their tumor characteristics.

Promega Highlights Commitment to Diagnostic Innovation

Alok Sharma, Global Clinical Market Director at Promega, said the FDA approval reflects the company’s commitment to developing diagnostic technologies that meet high standards for quality and regulatory compliance.

He emphasized that the OncoMate® MSI Dx Analysis System is intended to help connect patients with therapies that may be suitable for their disease, while supporting collaboration among diagnostic developers, pharmaceutical companies and healthcare professionals.

Sharma also highlighted the importance of working with pharmaceutical partners and clinicians to ensure that diagnostic results can contribute to treatment decisions.

The comments reflect Promega’s broader focus on developing molecular testing solutions that support precision medicine. As cancer treatment becomes increasingly guided by tumor biomarkers, reliable diagnostic technologies are important for identifying molecular characteristics that may influence therapeutic choices.

For patients, biomarker testing can provide information that helps clinicians evaluate available treatment options. For healthcare professionals, companion diagnostics can support decisions about whether a specific therapy is appropriate under its approved indication.

The FDA approval of OncoMate® for identifying MSI-H solid tumors as a companion diagnostic for KEYTRUDA® adds another application to Promega’s diagnostic portfolio.

Collaboration With Merck Supports Personalized Cancer Treatment

The latest approval was supported through a collaboration between Promega and Merck. Merck develops and markets KEYTRUDA®, an anti-PD-1 therapy used across multiple cancer indications.

The partnership reflects the growing importance of collaboration between diagnostic companies and pharmaceutical developers in precision oncology. As more therapies are developed for tumors with particular molecular characteristics, diagnostic testing plays an increasingly important role in determining which patients may be eligible for treatment.

KEYTRUDA® is an immune checkpoint inhibitor that targets programmed death receptor-1 (PD-1). PD-1 is a protein expressed on certain immune cells and functions as part of a regulatory pathway that can limit immune activity. Some cancer cells use this pathway to reduce the immune system’s ability to recognize and attack them.

By blocking PD-1, pembrolizumab is designed to help restore or enhance the immune system’s ability to respond to cancer cells. The therapy has been approved for a range of cancer indications, including specific biomarker-defined patient populations.

The MSI-H and dMMR biomarkers are relevant to certain immunotherapy treatment decisions because tumors with these characteristics may respond differently to immune checkpoint inhibition. Testing can therefore help identify patients who meet the biomarker requirements for an applicable treatment indication.

Through their collaboration, Promega and Merck are working to advance personalized medicine and expand access to diagnostic tools that support informed therapeutic choices. The newly approved companion diagnostic application provides another way for clinicians to use molecular information when considering KEYTRUDA® for eligible patients.

Previous FDA Clearance for Lynch Syndrome Evaluation

The latest FDA approval builds on the OncoMate® MSI Dx Analysis System’s earlier regulatory history.

Promega’s diagnostic system was previously cleared by the FDA as the first PCR-based molecular diagnostic designed to identify colorectal cancer patients who may benefit from additional testing to diagnose Lynch syndrome.

Lynch syndrome is an inherited condition associated with an increased risk of developing certain cancers, particularly colorectal and endometrial cancers. It is commonly linked to inherited changes in genes involved in DNA mismatch repair.

MSI testing can provide information that helps identify patients whose tumors may have characteristics associated with mismatch repair deficiency. In colorectal cancer, these findings may indicate the need for further evaluation to determine whether an individual has Lynch syndrome.

Identifying patients who may have Lynch syndrome can have implications beyond the treatment of an existing cancer. It may also inform genetic counseling, additional surveillance and risk assessment for the patient and potentially affected family members.

The previous FDA clearance established an important application for Promega’s MSI testing technology in the assessment of colorectal cancer patients who may require further investigation for an inherited cancer predisposition.

The new approval for use as a companion diagnostic for KEYTRUDA® expands the system’s role from supporting additional diagnostic evaluation to helping identify patients with MSI-H solid tumors who may be eligible for a specific immunotherapy.

Companion Diagnostic Approval for KEYTRUDA® Plus LENVIMA® in MSS Endometrial Cancer

In addition to its previous FDA clearance for colorectal cancer-related testing, the OncoMate® MSI Dx Analysis System has also received approval as a companion diagnostic for identifying patients with microsatellite stable (MSS) endometrial carcinoma who may benefit from treatment with KEYTRUDA® in combination with LENVIMA® (lenvatinib).

This application represents a distinct use of MSI testing in treatment selection. While the latest FDA approval concerns the identification of patients with MSI-H solid tumors for KEYTRUDA® treatment, the previously approved application involves patients with MSS endometrial carcinoma who may be eligible for the KEYTRUDA® and LENVIMA® combination.

LENVIMA® is an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. It is used in combination with KEYTRUDA® for certain approved cancer indications, including specified patients with advanced endometrial carcinoma.

The combination brings together two medicines with different mechanisms of action. Pembrolizumab targets the PD-1 immune checkpoint pathway, while lenvatinib inhibits the activity of multiple receptor tyrosine kinases involved in processes such as tumor growth and angiogenesis.

The companion diagnostic application helps identify patients with MSS endometrial carcinoma who may be considered for the combination under the relevant treatment indication.

These different regulatory applications demonstrate how MSI testing can support clinical decisions across distinct cancer types and therapeutic strategies. They also highlight the importance of interpreting biomarker results in the context of the specific FDA-approved indication for a medicine.

Promega stated that the relevant FDA approvals and clearances for the OncoMate® MSI Dx Analysis System apply to the United States and its territories.

International Regulatory Progress for Promega MSI Technology

Promega’s MSI technology has also achieved regulatory milestones outside the United States.

In the European Union, the company’s MSI technology is CE-marked under the In Vitro Diagnostic Regulation (IVDR). The European regulatory framework establishes requirements for the safety, performance and oversight of in vitro diagnostic medical devices.

The IVDR replaced the previous European regulatory framework for in vitro diagnostics and introduced more detailed requirements relating to clinical evidence, performance evaluation, quality management and post-market monitoring.

In China, Promega’s MSI technology has received approval from the National Medical Products Administration (NMPA) as a companion diagnostic for identifying patients with MSI-H solid tumors who may benefit from KEYTRUDA® treatment.

The NMPA approval represents another regulatory milestone for the company’s diagnostic platform and extends its companion diagnostic application into a major international healthcare market.

Together, the regulatory progress in the United States, European Union and China demonstrates Promega’s efforts to make its MSI testing technology available across multiple markets. These developments also reflect the increasing international importance of molecular diagnostics in supporting biomarker-based cancer treatment.

KEYTRUDA® Indication for MSI-H and dMMR Cancers

KEYTRUDA® is approved for adult and pediatric patients with unresectable or metastatic MSI-H or mismatch repair deficient cancer who have experienced disease progression following prior treatment and have no satisfactory alternative treatment options, according to the indication provided by the company.

The therapy’s biomarker-based indication underscores the importance of identifying MSI-H and dMMR tumor characteristics through appropriate diagnostic testing.

For patients with advanced cancer, determining whether a tumor has a specific biomarker can help clinicians assess available treatment options. Companion diagnostics provide a standardized approach to identifying patients who meet the biomarker requirements associated with a particular medicine.

The FDA approval of OncoMate® MSI Dx Analysis System for use with KEYTRUDA® provides a diagnostic option specifically designed to support the identification of patients with MSI-H solid tumors.

The approval does not mean that every patient with an MSI-H tumor will necessarily respond to treatment. Rather, the test provides biomarker information that can help healthcare professionals determine whether a patient meets the relevant criteria for treatment consideration.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., based in Rahway, New Jersey.

Advancing Biomarker-Based Cancer Care

The FDA approval of Promega’s OncoMate® MSI Dx Analysis System as a companion diagnostic for KEYTRUDA® represents an expansion of the company’s molecular diagnostic portfolio and its contribution to precision oncology.

The PCR-based assay is designed to evaluate MSI status in solid tumor tissue, helping clinicians identify patients with MSI-H tumors who may be eligible for treatment under the applicable KEYTRUDA® indication.

The approval builds on the system’s previous FDA clearance for supporting additional Lynch syndrome evaluation in colorectal cancer patients and its companion diagnostic application for identifying patients with MSS endometrial carcinoma who may benefit from KEYTRUDA® plus LENVIMA®.

Its CE marking under IVDR in the European Union and NMPA approval in China further demonstrate the international regulatory development of Promega’s MSI technology.

As biomarker-driven therapies continue to influence cancer treatment, diagnostic tests that identify relevant molecular characteristics are becoming an important part of clinical decision-making. The collaboration between Promega and Merck illustrates how diagnostic and pharmaceutical companies can work together to support personalized treatment strategies.

With the latest FDA approval, Promega’s OncoMate® MSI Dx Analysis System gains another defined role in identifying patients who may benefit from immunotherapy, supporting the broader integration of molecular diagnostics into cancer care.

About Promega Corporation

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and veterinary, agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. 

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter